This paper was written by myself, Dr Kyle Eberlin (the former president of the American Association for Hand Surgery, current director of the Harvard Plastic Surgery residency, and associate director of the MGH Hand Fellowship), Dr Justin McCarty, and Dr Walter Sussman.
https://onlinelibrary.wiley.com/doi/10.1002/pmrj.70146
Let me know what you think!
Three years in the making: AAPM&R’ guidance on PRP for knee OA.
A few key takeaways:
-Best supported for mild to moderate knee OA with persistent symptoms after conservative care
-Earlier treatment may do better
-LP-PRP and LR-PRP are both reasonable; superiority remains inconclusive
-Dose matters: target platelet dose of at least 10 billion
-Technique matters: ultrasound guidance, minimize RBCs, aspirate effusion when present
-For select severe OA cases with MRI-confirmed subchondral bone involvement, intraosseous PRP may also be considered
Most important: this paper emphasizes patient selection, informed consent, and realistic expectations. PRP may help pain and function, but patients should not expect cartilage regeneration.
Link:
https://onlinelibrary.wiley.com/doi/epdf/10.1002/pmrj.70144
*Disclosure: Since joining this committee in the fall of 2022, and writing this paper, Dr Latzka has become a consulting clinical advisor for Emcyte, with no ownership or stock in the company.